Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
AK117
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
AL8326
Lacuna Pharma Pty Ltd
- Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.
1 trial -
AL8326
Lacuna Pharma Pty Ltd
Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.
1 trial -
ALD518
CSL Behring GmbH
Oral Mucositis
1 trial -
ALDARA 5% cream, Keramod® gel
Lacuna Pharma Pty Ltd
Actinic keratosis
1 trial -
ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE
The George Institute
Germ Cell Tumors refractory to salvage chemotherapy
1 trial -
ALEXAN, 50 MG/ML, ROZTWÓR DO INFUZJI, Liposomal Annamycin
Moleculin Biotech
Acute Myeloid Leukemia
1 trial -
ALG-000184
Aligos Therapeutics
Chronic Hepatitis B Infection
1 trial -
ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten
Aligos Therapeutics
Chronic Hepatitis B Virus Infection
1 trial -
ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01
Lacuna Pharma Pty Ltd
Non-small-cell lung cancer
1 trial -
ALLO-501A
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
1 trial -
ALN-AAT02
Alnylam Netherlands B.V.
ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
1 trial -
ALN-AGT01 RVR
Alnylam Netherlands B.V.
Hypertension
1 trial -
ALN-RSV01
Alnylam Netherlands B.V.
Respiratory Syncytial Virus Infections
3 trials -
ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN
Novartis Pharmaceuticals
Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
1 trial -
ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011
Novartis Pharmaceuticals
Advanced HR+ breast cancer
1 trial -
ALPN-101
Vertex Pharmaceuticals (Australia) Pty.
Systemic Lupus Erythematosus
1 trial -
ALX-0061
Sanofi Pasteur
Lupus Erythematosus, Systemic
1 trial -
ALX1-11 50 mcg
Takeda
Osteoporosis
1 trial -
ALXN 2040, Placebo matching ALXN2040
Alexion Europe SAS
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
1 trial -
ALXN 2050, ALXN2050 Placebo Tablets
Alexion Europe SAS
Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
1 trial -
ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE
Alexion Europe SAS
Acromegaly
1 trial -
AMG 133, Placebo for AMG 133
Amgen
Overweight and Obesity
1 trial -
AMG 193
Amgen
Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources